Skip to main content

Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System

Written by Customer Service on . Posted in Public Companies.

Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide.

FRANKFURT, Germany, Aug. 08, 2025 (GLOBE NEWSWIRE) — In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology has announced the launch of its Chikungunya IgM/IgG Rapid Test, offering clinicians and public health authorities a fast, accessible diagnostic tool at the point of care. As cases continue to rise across tropical and subtropical regions, timely detection and differentiation from other arboviral infections like Dengue and Zika remain critical.

The test, based on immunochromatographic technology, enables reliable qualitative detection of Chikungunya-specific antibodies in human serum, plasma, or whole blood. This addition strengthens Anbio’s infectious disease diagnostics portfolio and supports public health efforts in responding to emerging outbreaks.

In parallel, Anbio is advancing the boundaries of decentralized molecular diagnostics with the launch of its new AP-100 Ultra-Fast PCR system, designed to bring laboratory-grade testing capabilities directly to the point of care.

“Outbreaks demand speed. The AP-100 collapses hours of traditional PCR into minutes, without compromising accuracy,” said Michael Lau, CEO of Anbio Biotechnology.

The AP-100 utilizes an advanced microfluidic thermal cycling system combined with high-efficiency enzymatic amplification chemistry, enabling direct processing of swab samples without the need for nucleic acid extraction. Its integrated design streamlines sample-to-result workflows, making it well-suited for deployment in both centralized laboratories and decentralized, point-of-care environments.

Key highlights:

  • 15-minute PCR results from raw sample to answer
  • Extraction-free workflow with no hazardous reagents
  • Compact 668g device for mobile or near-patient testing
  • Broad pathogen coverage, including COVID-19, Flu A/B, RSV, MP, and ADV
  • Lab-comparable accuracy validated against mainstream PCR platforms

While initially focused on respiratory infections, the AP-100 is designed as a flexible molecular platform. In line with its global infectious disease strategy, Anbio is expanding the assay portfolio to include tests for tuberculosis (TB) and human papillomavirus (HPV), extending its role from rapid outbreak response to sustained disease management.

“Whether it’s vector-borne fevers or respiratory pandemics, we believe diagnostics should move as fast as the threat,” Lau added.

With its combination of speed, mobility, and lab-grade precision, Anbio’s new-generation POCT PCR system strengthens healthcare capacity in both well-resourced and resource-limited settings, advancing global preparedness for infectious disease threats.

About Anbio Biotechnology
Anbio Biotechnology is a globally oriented in vitro diagnostics (IVD) company providing a broad range of solutions, including immunofluorescence, dry chemistry, chemiluminescence, molecular diagnostics, rapid testing and veterinary diagnostics. With operations across multiple regions, the company works to enhance the availability of reliable and timely diagnostics, supporting better decision-making in healthcare settings worldwide.

For more information about Anbio Biotechnology, follow us for the latest news and updates.

CONTACT: Contact:
connect@anbio.info

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.